Diatrizoate

613.91

613.91

204-223-6

5UVC90J1LK

760390|262168

DTXSID0044521

C47483

WHITE POWDER|Crystals from dilute dimethylformide|Crystals from ethanol (aqueous)

V - Various

2924299090

95.5

1.8

Solid

2.7±0.1 g/cm3

>300 °C

614.1°C at 760 mmHg

389.4±35.7 °C

1.790

Soluble in Methanol.

Amber Vial, -20°C Freezer

3.6X10-15 mm Hg at 25 deg C (est)

Henry's Law constant = 1.81X10-18 atm-cu m/mol at 25 °C (est)

pKa1 = 1.13 (carboxylic acid); pKa2 = 7.95 (amide) (est)

176.3 Ų [M+H]+ [CCS Type: TW, Method: calibrated with polyalanine and drug standards]|175.26 Ų [M+H]+

Rhombic needles. Slightly sweet taste; melting point 189-193 °C (decomposition); solubility in water at 20 °C: 89 g/100 mL /Meglumine diatrizoate/|pH between 6.0 & 7.6 /Diatrizoate Meglumine/|SOLN OF DIATRIZOATE SODIUM ARE CONSIDERABLY LESS VISCOUS THAN THOSE PREPD FROM DIATRIZOATE MEGLUMINE /SODIUM DIATRIZOATE/

NONH for all modes of transport

3

DG5950000

Preparations containing diatrizoate sodium should be protected from strong light.

P261, P272, P280, P285, P302+P352, P304+P341, P321, P333+P313, P342+P311, P363, P501

H317

SRP: Expired or waste pharmaceuticals shall carefully take into consideration applicable DEA, EPA, and FDA regulations. It is not appropriate to dispose by flushing the pharmaceutical down the toilet or discarding to trash. If possible return the pharmaceutical to the manufacturer for proper disposal being careful to properly label and securely package the material. Alternatively, the waste pharmaceutical shall be labeled, securely packaged and transported by a state licensed medical waste contractor to dispose by burial in a licensed hazardous or toxic waste landfill or incinerator.

The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, incl diatrizoate meglumine, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act. /Diatrizoate meglumine/|The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, incl diatrizoate sodium, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act. /Diatrizoate sodium/|The Generic Animal Drug and Patent Restoration act requires that each sponsor of an approved animal drug must submit to the FDA certain information regarding patents held for the animal drug or its method of use. The Act requires that this information, as well as a list of all animal drug products approved for safety and effectiveness, be made available to the public. Diatrizoate meglumine is included on this list. /Diatrizoate meglumine/|The Generic Animal Drug and Patent Restoration act requires that each sponsor of an approved animal drug must submit to the FDA certain information regarding patents held for the animal drug or its method of use. The Act requires that this information, as well as a list of all animal drug products approved for safety and effectiveness, be made available to the public. Diatrizoate sodium is included on this list. /Diatrizoate sodium/|For more FDA Requirements (Complete) data for DIATRIZOATE (6 total), please visit the HSDB record page.

|Danger|H317 (100%): May cause an allergic skin reaction [Warning Sensitization, Skin]|P261, P272, P280, P285, P302+P352, P304+P341, P321, P333+P313, P342+P311, P363, and P501|Aggregated GHS information provided by 10 companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Adverse effects of intravascular ... diatrizoate sodium include nasal and conjunctival symptoms (e.g., rhinitis, lacrimation, sneezing).

Diatrizoate was found in outflow from a municipal sewage treatment plant in Germany monitored from 1996-1998; the average concentration was 0.08 ug/L with a maximum of 8.7 ug/L reported; the 90th percentile concentration was 1.5 ug/L, and 22 of 25 samples were above the detection limit of 0.010 ug/L(1). The compound was detected at a concentration of 4 ug/L in surface water treatment employing bank filtration(2). Diatrizoate was detected at a concentration range of approximately 210 to 1.0X10+6 ng/L in an industrial waste water of the Netherlands in 2002. Total riverine discharge was estimated at 8.989 tons/yr in 2002(3). The average concentration of diatrizoate in six sewage treatment works in the United Kingdom sampled in 2001 was 42.1 ng/L; detection limit = 24.0 ng/L(4).

High osmolal radiocontrast agents like diatrizoate are cytotoxic to renal cells. The toxic effects include apoptosis, cellular energy failure, disruption of calcium homeostasis, and disturbance of tubular cell polarity, and are thought to be linked to oxidative stress.

Neurologic effects, including paraplegia, of diatrizoates may increase during aortography when diatrizoates are administered after hypertensive agents used to increase contrast; this increase is due to contraction of vessels in the splanchic circulation, which forces more of the contrast material into the vessels leading to the spine and spinal cord.|Incidence of delayed (more than 1 hour after administration) reactions (eg. hypersensitivity, fever, skin rash, flu-like symptoms, joint pain, flushing, pruritus, emesis, hypotension, dizziness) to intravenous contrast media may be increased in patients who have received interleukin-2; some symptoms may resemble a "recall" reaction to interleukin-2; supportive medical treatment may be necessary if symptoms are significant; there is some evidence that incidence is reduced if contrast media administration is delayed until 6 weeks after interleukin-2 administration.|Concurrent use /of chymopapain/ with diatrizoates may increase the risk of toxicity, especially if either agent enters the subarachnoid space; it is strongly recommended that diskography not be performed as part of the chemonucleolysis procedure.|Concurrent intravascular administration of diatrizoates with beta-adrenergic blocking agents may increase the risk of moderate to severe anaphylactoid reaction; also, hypotensive effects may be exacerbated; discontinuation of the beta-adrenergic blocking agent may be advisable before administration of contrast media in patients with other risk factors.|For more Interactions (Complete) data for DIATRIZOATE (9 total), please visit the HSDB record page.

LD50 Rat intraperitoneal 14,300 mg/kg|LD50 Rat intravenous 11,300 mg/kg|LD50 Mouse intravenous 8900 mg/kg|LD50 Guinea pig intraperitoneal 13 g/kg

Hysterosalpingography is not recommended during the menstrual period or when the menstrual flow is imminent, during pregnancy, or for 30 days after conization or curettage.|Cases of hyperthyroidism have been reported with the use of oral contrast media. Some of these patients reportedly had multinodular goiters which may have been responsible for the increased hormone synthesis in response to excess iodine. Administration of an intravascular iodinated radiopaque diagnostic agent to a hyperthyroid patient precipitated thyroid storm; a similar situation could follow administration of oral preparations of iodides. Therefore, caution should be exercised when administering enteral gastrointestinal radiopaque agents to hyperthyroid and euthyroid goiterous patients.|Dehydration and/or the risk of renal failure may be exacerbated, and in some cases may cause a shock-like state, in infants and young children, and in geriatric, azotemic, and dehydrated or debilitated patients, by the hypertonic contrast solutions of diatrizoates. /Diatrizoates/|In debilitated patients and in patients with electrolyte imbalances, postprocedural monitoring of hydration, serum osmolarity, electrolytes and clinical status is essential. In pediatric or severely debilitated patients, the maintenance of an open intravenous fluid line for rehydration may be advisable should hypotension or shock supervene. Electrolyte disturbances must be corrected prior to the administration of any hypertonic Gastrografin solutions.|For more Populations at Special Risk (Complete) data for DIATRIZOATE (11 total), please visit the HSDB record page.

Diatrizoate's production and use as a diagnostic contrast agent(1) may result in its release to the environment through various waste streams(SRC).

TERRESTRIAL FATE: Based on a classification scheme(1), an estimated Koc value of 10(SRC), determined from a structure estimation method(2), indicates that diatrizoate is expected to have very high mobility in soil(SRC). The estimated pKa of diatrizoate is 1.13(3), indicating that this compound will exist almost entirely in the anion form in the environment and anions generally do not adsorb more strongly to soils containing organic carbon and clay than their neutral counterparts(4). Volatilization from moist soil is not expected because the compound exists as an anion and anions do not volatilize. Diatrizoate is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 3.6X10-15 mm Hg at 25 °C(SRC), determined from a fragment constant method(5). Iodinated X-ray contrast agents are considered nondegradable by microorganisms(6).|AQUATIC FATE: Based on a classification scheme(1), an estimated Koc value of 10(SRC), determined from a structure estimation method(2), indicates that diatrizoate is not expected to adsorb to suspended solids and sediment(SRC). An estimated pKa of 1.13(3) indicates diatrizoate will exist almost entirely in the anion form at pH values of 5 to 9 and, therefore, volatilization from water or moist soil surfaces is not expected to be an important fate process(SRC). According to a classification scheme(4), an estimated BCF of 3(SRC), from an estimated log Kow of 1.37(5) and a regression-derived equation(6), suggests the potential for bioconcentration in aquatic organisms is low(SRC). Iodinated X-ray contrast agents are considered nondegradable by microorganisms(7).|ATMOSPHERIC FATE: According to a model of gas/particle partitioning of semivolatile organic compounds in the atmosphere(1), diatrizoate, which has an estimated vapor pressure of 3.8X10-15 mm Hg at 25 °C(SRC), determined from a fragment constant method(2), is expected to exist solely in the particulate phase in the ambient atmosphere. Particulate-phase diatrizoate may be removed from the air by wet or dry deposition(SRC). Diatrizoate does not contain chromophores that absorb at wavelengths >290 nm(4) and, therefore, is not expected to be susceptible to direct photolysis by sunlight(SRC).

Iodated diagnostic contrast agents such as diatrizoate are very persistent in aquatic environments(1). Diatrizoate is not expected to undergo hydrolysis in the environment due to the lack of functional groups that hydrolyze under environmental conditions(2). Diatrizoate does not contain chromophores that absorb at wavelengths >290 nm(2) and, therefore, is not expected to be susceptible to direct photolysis by sunlight(SRC).

An estimated BCF of 3 was calculated in fish for diatrizoate(SRC), using an estimated log Kow of 1.37(1) and a regression-derived equation(2). According to a classification scheme(3), this BCF suggests the potential for bioconcentration in aquatic organisms is low(SRC).

Using a structure estimation method based on molecular connectivity indices(1), the Koc of diatrizoate can be estimated to be 10(SRC). According to a classification scheme(2), this estimated Koc value suggests that diatrizoate is expected to have very high mobility in soil. Iodinated diagnostic contrast agents such as diatrizoate leach readily into groundwater(3). The estimated pKa of diatrizoate is 1.13(4), indicating that this compound will exist almost entirely in the anion form in the environment and anions generally do not adsorb more strongly to soils containing organic carbon and clay than their neutral counterparts(5).

The estimated pKa of diatrizoate is 1.13(1), indicating that this compound will primarily exist as an anion in the aqueous environment and anions do not volatilize from water or moist soil surfaces. Diatrizoate is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 3.6X10-15 mm Hg(SRC), determined from a fragment constant method(2).

DRINKING WATER: It has been suggested that in all countries with an advanced medical care system, x-ray contrast media can be expected to be present in sewage effluent which, therefore, leads to potential contamination of receiving waters(1). Diatrizoate was found at an average concentration of 1.2 ug/L in raw drinking water well samples taken from an area close to a bank infiltration treatment site in Berlin, Germany(2). Another study based in Germany reported a concentration range of <0.01 to 0.079 ug/L, detection limit of 0.010 ug/L(3).|SURFACE WATER: In a study based in Berlin, Germany, diatrizoate was found in surface water samples (influenced by municipal treatment effluent) at an average concentration of 2 ug/L and in surface water samples after bank filtration at an average concentration of 4 ug/L(1). Diatrizoate was found in 25/25 samples taken from unspecified German rivers and streams monitored from 1996-1998; the average concentration was 0.23 ug/L with a maximum concentration of approximately 100 ug/L reported; the 90th percentile concentration was 6.4 ug/L, and 23 samples were above the detection limit of 0.010 ug/L(2). The compound was reported at median concentrations of 89 upstream of a sewage treatment plant at Ulm/Boefingen and 155 ng/L downstream at Leipheim (maximum of 190 and 580 ug/L, respectively) both located on the River Danube in South Germany, sampling conducted in 2004(3). Diatrizoate concentrations in surface water of the Netherlands between 1996 and 2005 ranged from approximately 20 to 200 ng/L with an outlier at 300 ng/L(4).

Although problems in humans have not been documented, since diatrizoates are distributed unchanged into breast milk, temporary discontinuation of breast-feeding is recommended for at least 24 hours following administration.

Occupational exposure to diatrizoate may occur through dermal contact with this compound at workplaces where diatrizoate is produced or used. Monitoring data indicate that the general population may be exposed to diatrizoate via ingestion of and dermal contact with water containing this compound. Exposure to diatrizoate among the general population may also occur to those administered the drug. (SRC)

Used, alone or in combination, for a wide variety of diagnostic imaging methods, including angiography, urography, cholangiography, computed tomography, hysterosalpingography, and retrograde pyelography. It can be used for imaging the gastrointestinal tract in patients allergic to barium.

Contrast Media|Osmotic agent; the osmotic effect of diatrizoate sodium, and diatrizoate meglumine and diatrizoate sodium combination solutions draws fluid into the intestine, thus helping to dislodge the meconium impaction. /Diatrizoates/|Diagnostic aid, radiopaque; organic iodine compounds block x-rays as they pass through the body, thereby allowing body structures containing iodine to be delineated in contrast to those structures that do not contain iodine. The degree of opacity produced by these iodinated organic compounds is directly proportional to the total amount (concentration and volume) of the iodinated contrast agent in the path of the x-rays.|Diagnostic aid (radiopaque medium). /Meglumine Diatrizoate/|For more Therapeutic Uses (Complete) data for DIATRIZOATE (24 total), please visit the HSDB record page.

Contrast Media|FDA Pregnancy Risk Category: C /RISK CANNOT BE RULED OUT. Adequate, well controlled human studies are lacking, and animal studies have shown risk to the fetus or are lacking as well. There is a chance of fetal harm if the drug is given during pregnancy; but the potential benefits may outweigh the potential risk./ /Diatrizoates, systemic (Parenteral solutions)/|The most common complication of splenoportography is internal bleeding. Fatal hemorrhage has occurred rarely, but leakage of up to 300 mL of blood from the spleen is apparently common. Blood transfusions and rarely splenectomy may be required.|Intestinal necrosis and GI tract perforation leading to death have been associated with rectal administration of diatrizoate solutions in the investigational treatment of meconium ileus in infants.|For more Drug Warnings (Complete) data for DIATRIZOATE (37 total), please visit the HSDB record page.

Diatrizoate is the most commonly used water-soluble, iodinated, radiopaque x-ray contrast medium. Radiopaque agents are drugs used to help diagnose certain medical problems. They contain iodine, which blocks x-rays. Depending on how the radiopaque agent is given, it localizes or builds up in certain areas of the body. The resulting high level of iodine allows the x-rays to make a "picture" of the area. The areas of the body in which the radiopaque agent localizes will appear white on the x-ray film. This creates the needed distinction, or contrast, between one organ and other tissues. The contrast will help the doctor see any special conditions that may exist in that organ or part of the body.

Substances used to allow enhanced visualization of tissues. (See all compounds classified as Contrast Media.)

However, it is not metabolized but excreted unchanged in the urine, each diatrizoate molecule remaining "obligated" to its sodium moiety. The liver and small intestine provide the major alternate route of excretion for diatrizoate. Injectable radiopaque diagnostic agents are excreted unchanged in human milk. Saliva is a minor secretory pathway for injectable radiopaque diagnostic agents.|Diatrizoate meglumine is excreted in breast milk following intravascular administration.|Diatrizoate sodium is very poorly absorbed from the GI tract. In some patients, especially infants and patients with engorgement of the intestinal mucosa, small amounts of the drug may be absorbed from the GI tract and occasionally produce partial visualization of the urinary tract. Following intravesical instillation of diatrizoate sodium, only small amounts of the drug are absorbed into blood through the bladder. Some absorption of diatrizoate sodium into blood may also occur through serous membranes such as the peritoneum or pleura. The drug is rapidly absorbed after IM or subcutaneous injection.|Diatrizoate sodium is rapidly distributed throughout extracellular fluid following intravascular administration. Less than 5% of the drug appears to be bound to plasma proteins.|Diatrizoates, when administered intravenously, cross the placenta and are evenly distributed in fetal tissues. Intra-amniotic injection of diatrizoates has been reported to suppress the fetal thyroid gland.|For more Absorption, Distribution and Excretion (Complete) data for DIATRIZOATE (7 total), please visit the HSDB record page.

The metabolic behavior of 3-amino-5-acetamido-2,4,6-triiodobenzoate and 3,5-diamino-2,4,6 -triiodobenzoate was examined. Drug retention in rabbits was monitored with a gamma camera. Diatrizoate was partially deacetylated by liver microsomes to 3-amino-5-acetamido-2,4,6-triiodobenzoate and 3,4-diamino-2,4,6-triiodobenzoate. The rabbit converted some of 3,5-diamino-2,4,6-trioodobenzoate to a urinary metabolite which was similar to that formed by liver microsomes.

Following rapid IV injection of diatrizoate sodium in patients with normal renal function, blood drug concentrations peak immediately, fall rapidly within 5-10 minutes, and then decline with a halflife of about 30-60 minutes. In patients with severely impaired renal function, the blood drug halflife is reported to be 20-140 hours.

Diatrizoate is an iodine-containing X-ray contrast agent. Iodated contrast agents were among the first contrast agents developed. Iodine is known to be particular electron-dense and to effectively scatter or stop X-rays. A good contrast agent requires a high density of electron-dense atoms. Therefore, the more iodine, the more "dense" the x-ray effect. Iodine based contrast media are water soluble and harmless to the body. These contrast agents are sold as clear colorless water solutions, the concentration is usually expressed as mg I/ml. Modern iodinated contrast agents can be used almost anywhere in the body. Most often they are used intravenously, but for various purposes they can also be used intraarterially, intrathecally (the spine) and intraabdominally - just about any body cavity or potential space.|Radiocontrast medium induced nephrotoxicity is a major clinical problem. There is considerable interest in reducing the incidence of acute renal failure due to the use of radiocontrast media (RCM). Reduction of renal blood flow and direct toxic effect on renal tubular epithelial cells have been postulated as major causes of RCM nephropathy. Understanding the molecular mechanisms by which RCM cause cell damage may allow the development of pharmacological therapy to prevent their nephrotoxicity. In this work we have investigated the signaling pathways that may be affected by RCM. The incubation of human renal tubular proximal cells with sodium diatrizoate, iopromide and iomeprol caused a marked dephosphorylation of the kinase Akt on Ser473 within 5min of incubation. RCM also caused a decrease in cell viability, which was substantially alleviated by transfecting the cells with a constitutively active form of Akt. Further downstream targets of Akt, including the Forkhead family of transcription factors FKHR and FKHRL1, were also dephosphorylated by RCM at Thr24 and Thr32, respectively. The P70S6 kinase was also dephosphorylated at Thr389 and Ser371 by RCM. However there was a more dramatic decrease in phosphorylation of the phosphorylated form of mammalian target of rapamycin (mTOR) and of the extracellular-signal regulated kinases (ERK) 1/2 caused by sodium diatrizoate than by iopromide. These results demonstrate the effect of RCM on some intracellular signaling pathways that may allow understanding of the mechanism of their toxicity and may allow the development of strategies to overcome their adverse effects.

For major life-threatening reactions, careful monitoring of vital signs and emergency therapy, including artificial respiration with oxygen, if needed for respiratory depression, and cardiac massage in the event of cardiac arrest. To restore blood pressure, administration of intravenous fluids and/or vasopressors. If hypotension requires the use of vasopressors, slow infusion of ... norepinephrine or ... phenylephrine, appropriately diluted. If hypotension is due to increased vagal activity (vasovagal reaction), intravenous administration of atropine, repeated in one to two hours if needed. Other specific treatment may include: Epinephrine for acute allergic-like or anaphylactoid reactions; Diphenhydramine for minor allergic-like reactions; diazepam or phenobarbital to control convulsions ...|Rapid removal of sodium diatrizoate in patient with renal failure requires hemodialysis.|/SRP:/ Immediate first aid: Ensure that adequate decontamination has been carried out. If patient is not breathing, start artificial respiration, preferably with a demand valve resuscitator, bag-valve-mask device, or pocket mask, as trained. Perform CPR if necessary. Immediately flush contaminated eyes with gently flowing water. Do not induce vomiting. If vomiting occurs, lean patient forward or place on the left side (head-down position, if possible) to maintain an open airway and prevent aspiration. Keep patient quiet and maintain normal body temperature. Obtain medical attention. /Poisons A and B/|/SRP:/ Basic treatment: Establish a patent airway (oropharyngeal or nasopharyngeal airway, if needed). Suction if necessary. Watch for signs of respiratory insufficiency and assist ventilations if needed. Administer oxygen by nonrebreather mask at 10 to 15 L/min. Monitor for pulmonary edema and treat if necessary ... . Monitor for shock and treat if necessary ... . Anticipate seizures and treat if necessary ... . For eye contamination, flush eyes immediately with water. Irrigate each eye continuously with 0.9% saline (NS) during transport ... . Do not use emetics. For ingestion, rinse mouth and administer 5 mL/kg up to 200 mL of water for dilution if the patient can swallow, has a strong gag reflex, and does not drool ... . Cover skin burns with dry sterile dressings after decontamination ... . /Poisons A and B/|/SRP:/ Advanced treatment: Consider orotracheal or nasotracheal intubation for airway control in the patient who is unconscious, has severe pulmonary edema, or is in severe respiratory distress. Positive-pressure ventilation techniques with a bag valve mask device may be beneficial. Consider drug therapy for pulmonary edema ... . Consider administering a beta agonist such as albuterol for severe bronchospasm ... . Monitor cardiac rhythm and treat arrhythmias as necessary ... . Start IV administration of D5W /SRP: "To keep open", minimal flow rate/. Use 0.9% saline (NS) or lactated Ringer's if signs of hypovolemia are present. For hypotension with signs of hypovolemia, administer fluid cautiously. Watch for signs of fluid overload ... . Treat seizures with diazepam or lorazepam ... . Use proparacaine hydrochloride to assist eye irrigation ... . /Poisons A and B/

/SIGNS AND SYMPTOMS/ Anaphylactic reactions: Anaphylactic reactions, including fatalities, have been reported with the use of Gastrografin. Patients at increased risk include those with a history of a previous reaction to a contrast medium, patients with a known sensitivity to iodine, and patients with a known clinical hypersensitivity (bronchial asthma, hay fever, and food allergies). Medical personnel trained in the treatment of anaphylactic reactions and the necessary drugs and medical equipment should always be readily available when Gastrografin is used.|/SIGNS AND SYMPTOMS/ Neurologic effects, including paraplegia, of diatrizoates may increase during aortography when diatrizoates are administered after hypertensive agents used to increase contrast; this increase is due to contraction of vessels in the splanchic circulation, which forces more of the contrast material into the vessels leading to the spine and spinal cord.|/SIGNS AND SYMPTOMS/ Other adverse effects of intravascular diatrizoate meglumine and diatrizoate sodium include nasal and conjunctival symptoms (e.g., rhinitis, lacrimation, sneezing), urticaria, pruritus, rash, angioedema, edema, weakness, pallor, cramps, sweating, severe retching and choking, and metallic taste. Neutropenia, erythrocyte sludging and agglutination, crenation, and transient changes in coagulation may occur; rarely disseminated intravascular coagulation resulting in death has been reported. Infrequently, immediate or delayed chills can occur, sometimes with fever. Salivary gland swelling may occur a few hours to 4 days after administration of the medium and persist several days.|/SIGNS AND SYMPTOMS/ Arteriography of arterial trunks providing blood supply to spinal-artery branches or selective spinal arteriography can cause mild to severe muscle spasm; severe neurologic reactions including permanent paralysis, paraplegia, and quadriplegia have occasionally been reported|For more Human Toxicity Excerpts (Complete) data for DIATRIZOATE (18 total), please visit the HSDB record page.

Amidotrezoate

66% (660 mg per mL) of diatrizoate meglumine and 10% (100 mg per mL) of diatrizoate sodium with 36.7% (367 mg per mL) of iodine (Rx) /Tradename:/ Gastrografin; MD-Gastroview. /Diatrizoates/|GRADE: USP (as solution for injection) /Sodium diatrizoate/

Information available in 2005 indicated that Meglumine diatrizoate was used in the manufacture of pharmaceutical preparations in the following countries: Algeria, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Colombia, Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, India, Israel, Italy, Luxembourg, Netherlands, New Zealand, Norway, Poland, Portugal, Romania, Russian Federation, Singapore, South Africa, Spain, Sweden, Switzerland, Turkey, United Kingdom, United States, Yugoslavia (1,2) /Meglumine diatrizoate/|Information available in 2005 indicated that Sodium diatrizoate was used in the manufacture of pharmaceutical preparations in the following countries: Algeria, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, India, Israel, Italy, Luxembourg, Netherlands, New Zealand, Norway, Poland, Portugal, Romania, Russian Federation, Singapore, South Africa, Spain, Sweden, Switzerland, Turkey, United Kingdom, United States, Yugoslavia (1,2) /Meglumine diatrizoate/|Information available in 2005 indicated that Lysine diatrizoate was used in the manufacture of pharmaceutical preparations in the following countries: Austria, Germany, Hungary (1,2)|Information available in 2005 indicated that Calcium diatrizoate was used in the manufacture of pharmaceutical preparations in the following countries: Brazil, Spain (1,2)

Analyte: Diatrizoate; matrix: blood, tissue; procedure: high performance liquid chromatography with ultraviolet detection at 254 nm; limit of detection: 710 ng/mL|Analyte: Diatrizoate; matrix: formulations; procedure: high performance liquid chromatography with ultraviolet detection at 238 nm|IODINATED RADIOCONTRAST AGENTS, INCLUDING DIATRIZOIC ACID, WERE SEPARATED BY HIGH PRESSURE LIQUID CHROMATOGRAPHY.|Analyte: diatrizoic acid; matrix: chemical identification; procedure: thin-layer chromatography with comparison to standards|For more Analytic Laboratory Methods (Complete) data for DIATRIZOATE (30 total), please visit the HSDB record page.

Human Drugs -> FDA Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) -> Active Ingredients